Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

By Ludwig Burger FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple ...

Roche's late-stage trial of fenebrutinib, a multiple sclerosis drug candidate, met its primary goal. The trial demonstrated a significant reduction in annualized relapse rates compared to ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...

BUFFALO, N.Y. — University at Buffalo researcher Murali Ramanathan, PhD, has used artificial intelligence (AI) since its nascent days while exploring possible treatments for multiple sclerosis (MS) ...

VANCOUVER, BC / ACCESS Newswire / August 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

A team of scientists led by the Institute for Glial Sciences (IGS) at Case Western Reserve University’s School of Medicine has discovered a built-in “brake” that controls when key brain cells mature.

Researchers at the University of Turku, Finland, have discovered a new biomarker that can predict the progression of multiple sclerosis (MS). The thickness of the inflammatory cell rim surrounding ...